# A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants

> **NCT02908685** · PHASE2 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 231 (actual)

## Conditions studied

- Muscular Atrophy, Spinal

## Interventions

- **DRUG:** Placebo
- **DRUG:** Risdiplam

## Key facts

- **NCT ID:** NCT02908685
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-10-19
- **Primary completion:** 2019-09-06
- **Final completion:** 2023-10-02
- **Target enrollment:** 231 (ACTUAL)
- **Last updated:** 2024-04-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02908685

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02908685, "A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Risdiplam (RO7034067) in Type 2 and 3 Spinal Muscular Atrophy (SMA) Participants". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02908685. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*